相关实验视频

Updated: Jun 30, 2025

In Vitro Thrombosis Test for Ventricular Assist Devices

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

用未分离的肝素治疗假血栓的治疗方法

Semih Kalkan¹, Mustafa Ozan Gürsoy², Ahmet Güner³

¹Department of Cardiology, Basaksehir Cam Sakura City Hospital, Istanbul, Turkiye.

International journal of cardiology

|March 19, 2024

概括

在特定患者中,未分离的肝素 (UFH) 输液可以成为对假体血栓症 (PVT) 的有益治疗方法. 阻塞性血栓性质和更大的血栓面积是预测不成功UFH治疗结果的关键因素.

科学领域:

心脏病学心脏病学
心血管外科心血管外科
内部医学内部医学

背景情况:

假体血栓 (PVT) 是一种严重并发症,具有高风险的治疗选择.
无分离肝素 (UFH) 输注为不适合接受手术或血栓抑制疗法 (TT) 的患者提供了潜在的替代方案.

研究的目的:

评估UFH输液在患有阻塞性和非阻塞性PVT的患者的疗效和安全性.
为了确定治疗成功或失败的预测因素,用UFH治疗PVT.

主要方法:

观察性回顾性研究设计.
招募PVT患者,他们对TT和手术有禁忌.
根据减少血栓负担,死亡率和重大并发症评估治疗结果.

主要成果:

在136名患者中,66名患者 (48.5%) 获得了成功的UFH治疗,血栓回归率>75%,没有重大并发症.
失败的组 (56名患者) 血栓减少<50%,其中14人出现重大并发症.
阻塞性PVT,更大的血栓面积和更长的UFH治疗时间独立地与治疗失败有关.

结论:

对某些PVT患者来说,UFH输液可能是一个有益的治疗策略.
血栓的阻塞性和大小是UFH治疗在PVT中的成功的关键决定因素.

关键词:

人造心脏门是一种假心脏门.外科手术手术手术血栓溶解是一种血栓溶解.血栓形成的原因之一是血栓形成.没有分离的肝素.

更多相关视频

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Autologous Endothelial Progenitor Cell-Seeding Technology and Biocompatibility Testing For Cardiovascular Devices in Large Animal Model

Autologous Endothelial Progenitor Cell-Seeding Technology and Biocompatibility Testing For Cardiovascular Devices in Large Animal Model

Published on: September 9, 2011

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...